Literature DB >> 3958486

The survival of treated hypertensive patients and their causes of death: a report from the DHSS hypertensive care computing project (DHCCP).

C J Bulpitt, D G Beevers, A Butler, E C Coles, D Hunt, A D Munro-Faure, R B Newson, P W O'Riordan, J C Petrie, B Rajagopalan.   

Abstract

A prospective study has been carried out to determine the causes of death and risk factors for survival in 4994 patients referred with a diagnosis of hypertension to hospital specialist clinics and 457 patients treated by their general practitioners for this condition. At the time of entering the prospective study, 69% of the patients were already being treated for hypertension. Four hundred and eleven patients have died, and their causes of death and death rates have been compared with the rates for the population of England and Wales. Ischaemic heart disease accounted for over one-third of the deaths and stroke for one-fifth. The death rates for these conditions were two to five times those expected for men and women aged 50-59 years and up to twice the rate expected for the age group 60-69 years. Survival in these selected patients was impaired by the following independent risk indicators: cigarette smoking, previous history of myocardial infarction or stroke, diagnosis of angina, impaired renal function and raised blood sugar. The following factors were not independent positive risk factors: smoking a pipe or cigars, obesity, a low plasma potassium and an elevated serum uric acid.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3958486     DOI: 10.1097/00004872-198602000-00015

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  10 in total

1.  Joint British recommendations on prevention of coronary heart disease in clinical practice. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association.

Authors: 
Journal:  Heart       Date:  1998-12       Impact factor: 5.994

Review 2.  Selective versus nonselective beta adrenoceptor antagonists in hypertension.

Authors:  L M Van Bortel; A J Ament
Journal:  Pharmacoeconomics       Date:  1995-12       Impact factor: 4.981

3.  Effects of doxazosin and atenolol on the fibrinolytic system in patients with hypertension and elevated serum cholesterol.

Authors:  J H Jansson; B Johansson; K Boman; T K Nilsson
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 4.  ACE inhibitors and proteinuria.

Authors:  R T Gansevoort; D de Zeeuw; P E de Jong
Journal:  Pharm World Sci       Date:  1996-12

Review 5.  Experiences from hypertension trials. Impact of other risk factors.

Authors:  O Samuelsson
Journal:  Drugs       Date:  1988       Impact factor: 9.546

6.  Risk of serious morbidity associated with hydralazine versus methyldopa treatment in hypertensive patients.

Authors:  P J Franks; K Hartley; P F Bulpitt; C J Bulpitt
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 7.  Proteinuria as a prognostic factor during long term hypertensive care.

Authors:  O Samuelsson
Journal:  Drugs       Date:  1988       Impact factor: 9.546

8.  Impact of treating hyperlipidemia or hypertension to reduce the risk of death from coronary artery disease.

Authors:  S Perreault; M Dorais; L Coupal; G Paradis; M R Joffres; S A Grover
Journal:  CMAJ       Date:  1999-05-18       Impact factor: 8.262

Review 9.  Microalbuminuria in hypertension.

Authors:  Paolo Palatini
Journal:  Curr Hypertens Rep       Date:  2003-06       Impact factor: 5.369

10.  Survival in treated hypertension: follow up study after two decades.

Authors:  O K Andersson; T Almgren; B Persson; O Samuelsson; T Hedner; L Wilhelmsen
Journal:  BMJ       Date:  1998-07-18
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.